Basic and clinical study of inhalation of inactivated mycobacterium vaccine in the treatment of Novel coronavirus pneumonia (COVID-19)

Efficacy evaluation of inhalation of mycobacterium vaccae injection for treating Novel coronavirus pneumonia (COVID-19) and the mechanism study of prevention and treatment of respiratory virus infection

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030016

Enrollment

Unknown

Registered

2020-02-19

Start date

2020-02-04

Completion date

Unknown

Last updated

2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

1:inhalate the mycobacterium vaccae for injection

2:inhalate Physiological saline

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients aged >=18 years with novel coronavirus pneumonia who agreed to participate in this trial and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant women; 2. Patients with a history of angina pectoris, myocardial infarction and other serious cardiovascular diseases; 3. The researchers judged that this study was not in the interests of patients.

Design outcomes

Primary

Measure	Time frame
viral negative-transforming time;30-day cause-specific mortality;30-day cause-adverse events;30-day all-cause mortality;co-infections;Time from severe and critical patients to clinical improvement;Others (liver function, kidney function, myocardial enzyme);	—

Countries

China

Contacts

Public ContactChaoqian Li

Department of respiratory medicine, the First Affiliated Hospital of Guangxi Medical University

2534776680@qq.com+86 13807887867

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026